Valneva Competitors and Similar CompaniesClear all
Valneva's competitors and similar companies include Novimmune and Emergent Biosolutions.
 Valneva Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. |  Novimmune Novimmune is a company that focuses on its bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience. |  Emergent Biosolutions Emergent Biosolutions is a biopharmaceutical company that provides vaccines and therapeutics against public health threats. | |
Founding Date | Founding Date 2013 | Founding Date 1998 | Founding Date 1998 |
Type | Type Public | Type Private | Type Public |
Tags | |||
Locations | Locations Plan-les-Ouates, CH HQ | Locations Gaithersburg, US HQ Mississauga, CA Winnipeg, CA Dublin, IE London, GB Canton, US Lansing, US see more | |
Employees | Employees 713 | Employees 80 | Employees 90044% decrease |
Valuation ($) | Valuation ($) 482.5 m | Valuation ($) N/A | Valuation ($) 493.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) €157.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $742.9m (FY, 2025) |
Cost of goods | Cost of goods €8.2m (FY, 2025) | Cost of goods N/A | Cost of goods $326.2m (FY, 2025) |
Gross profit | Gross profit €177.7m (FY, 2025) | Gross profit N/A | Gross profit $416.7m (FY, 2025) |
Net income | Net income (€115.2m) (FY, 2025) | Net income N/A | Net income $52.6m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 51.7m | Total funding raised $ 239.1m | Total funding raised $ 34.5m |
For sources of this data, please see the company profile
View Company Profiles
Novimmune
HQ
Plan-les-Ouates, CH
Employees
80
Novimmune is a company that focuses on its bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.
View companyEmergent Biosolutions
HQ
Gaithersburg, US
Employees
900↓ 44% decrease
Emergent Biosolutions is a biopharmaceutical company that provides vaccines and therapeutics against public health threats.
View company